[go: up one dir, main page]

MX2015017629A - Combinaciones farmaceuticas. - Google Patents

Combinaciones farmaceuticas.

Info

Publication number
MX2015017629A
MX2015017629A MX2015017629A MX2015017629A MX2015017629A MX 2015017629 A MX2015017629 A MX 2015017629A MX 2015017629 A MX2015017629 A MX 2015017629A MX 2015017629 A MX2015017629 A MX 2015017629A MX 2015017629 A MX2015017629 A MX 2015017629A
Authority
MX
Mexico
Prior art keywords
combination
methyl
quinolin
amide
prevention
Prior art date
Application number
MX2015017629A
Other languages
English (en)
Inventor
Samit Hirawat
Emmanuelle Ditomaso
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2015017629A publication Critical patent/MX2015017629A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una combinación farmacéutica que comprende: (a) un inhibidor de fosfatidilinositol-3-quinasa seleccionado a partir de 2-metil-2-[4-(3-metil-2-oxo-8-quinolin.-3-il-2,3-dihidro-imidazo[ 4,5-c]quinolin-1-il)-fenil]-propionitrilo, 5-(2 6-di-morfolin-4-il-pirimidin-4-il)-4-trifuorometil-piridin-2-ilam ina, 2-amida 1-({4-metil-5-[2-(2,2,2-tri-fluoro-1,1-dimetil-etil)p iridin-4-il]-tiazol-2-il}amida) del ácido (S)-pirrolidin-1,2-dicar boxílico o cualquier sal farmacéuticamente aceptable de los mismos, y (b) un inhibidor de la quinasa del linfoma anaplásico, particularmente para uso en el tratamiento o prevención de una enfermedad proliferativa; usos de tal combinación en el tratamiento o prevención de enfermedades proliferativas; composiciones farmacéuticas de la combinación de dichos agentes terapéuticos y métodos de tratamiento de una enfermedad proliferativa en un sujeto que comprende administrar a dicho sujeto una cantidad terapéuticamente efectiva de dicha combinación.
MX2015017629A 2013-06-18 2014-06-16 Combinaciones farmaceuticas. MX2015017629A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361836347P 2013-06-18 2013-06-18
PCT/IB2014/062271 WO2014203152A1 (en) 2013-06-18 2014-06-16 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
MX2015017629A true MX2015017629A (es) 2016-04-15

Family

ID=51492386

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015017629A MX2015017629A (es) 2013-06-18 2014-06-16 Combinaciones farmaceuticas.

Country Status (10)

Country Link
US (1) US20160129003A1 (es)
EP (1) EP3010505A1 (es)
JP (1) JP2016522247A (es)
KR (1) KR20160020502A (es)
CN (1) CN105338980A (es)
AU (1) AU2014282798A1 (es)
BR (1) BR112015030578A2 (es)
CA (1) CA2914310A1 (es)
MX (1) MX2015017629A (es)
WO (1) WO2014203152A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101772134B1 (ko) 2015-04-14 2017-08-29 한국화학연구원 N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2016167511A2 (ko) * 2015-04-14 2016-10-20 한국화학연구원 N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
JP2019064976A (ja) * 2017-10-03 2019-04-25 国立大学法人 熊本大学 抗がん剤
JP2022539208A (ja) 2019-07-03 2022-09-07 スミトモ ファーマ オンコロジー， インコーポレイテッド チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
CA3188639A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
EP4298099A1 (en) 2021-02-25 2024-01-03 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
JP2025509672A (ja) 2022-03-17 2025-04-11 インサイト・コーポレイション Ｊａｋ２ ｖ６１７ｆ阻害剤としての三環式尿素化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2287156B1 (en) 2003-08-15 2013-05-29 Novartis AG 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
TWI432427B (zh) 2006-10-23 2014-04-01 Cephalon Inc 作為ＡＬＫ及ｃ-ＭＥＴ抑制劑之２，４-二胺基嘧啶之融合雙環衍生物
PL2091918T3 (pl) * 2006-12-08 2015-02-27 Novartis Ag Związki i kompozycje jako inhibitory kinazy białkowej
BRPI0915901A2 (pt) * 2008-07-11 2015-10-27 Novartis Ag combinação de (a) um inibidor de fosfoinositídeo 3-quinase e (b) um modulador da via ras/raf/mek
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
MY159850A (en) 2009-06-10 2017-02-15 Chugai Pharmaceutical Co Ltd Tetracyclic compounds
EP2908132B8 (en) * 2011-03-02 2019-06-12 Nestec S.A. Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
WO2012162372A1 (en) * 2011-05-24 2012-11-29 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors
KR20140072028A (ko) * 2011-08-31 2014-06-12 노파르티스 아게 Pi3k- 및 mek-억제제의 상승작용적 조합물
WO2014028566A1 (en) * 2012-08-16 2014-02-20 Novartis Ag Combination of pi3k inhibitor and c-met inhibitor

Also Published As

Publication number Publication date
CN105338980A (zh) 2016-02-17
KR20160020502A (ko) 2016-02-23
WO2014203152A1 (en) 2014-12-24
EP3010505A1 (en) 2016-04-27
AU2014282798A1 (en) 2015-12-03
JP2016522247A (ja) 2016-07-28
US20160129003A1 (en) 2016-05-12
CA2914310A1 (en) 2014-12-24
BR112015030578A2 (pt) 2017-07-25

Similar Documents

Publication Publication Date Title
MX2015017629A (es) Combinaciones farmaceuticas.
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
RU2014120792A (ru) Способ лечения стромальных опухолей желудочно-кишечного тракта
HK1212240A1 (en) Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
MX2017010287A (es) Composiciones farmaceuticas que comprenden n-(3,5-dimetoxifenil)-n '-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il)quinoxalin-6-il]eta no-1,2-diamina.
IL288508A (en) History of n-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl)tetrahydro-h2-pyran-4-carboxamide and related compounds as human ctps1 inhibitors to treat proliferative diseases
MX2015000746A (es) Terapia de combinacion de inhibidores para el receptor del factor de crecimiento insulinico tipo 1 (igf1r) y fosfatidilinositol 3-cinasa (pi3k).
WO2007058990A3 (en) Therapy using cytokine inhibitors
JP2014525454A5 (es)
MX369518B (es) Combinacion de inhibidor de p13k e inhibidor de c-met.
MX2015017058A (es) Combinaciones farmaceuticas de un inhibidor de pi3k y un agente de desestabilizacion de microtubulos.
EA201990664A1 (ru) Производные 5-[2-(пиридин-2-иламино)-1,3-тиазол-5-ил]-2,3-дигидро-1h-изоиндол-1-она и их применение в качестве двойных ингибиторов фосфатидилинозитол-3-киназ дельта и гамма
EA025948B1 (ru) КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR
MX390667B (es) Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos.
WO2018027084A3 (en) Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
FI3661510T3 (fi) Menetelmiä käyttäytymismuutosten hoitamiseksi
ZA202101118B (en) A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis
RU2017111848A (ru) Новая фармацевтическая композиция для профилактики и/или лечения недержания мочи
WO2007113243A3 (en) Use of pde 5 inhibitors for the treatment of overactive bladder
MX379191B (es) Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension.
BR112015012497A2 (pt) combinações farmacêuticas
NZ602807A (en) 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor
MX2016010482A (es) Combinaciones farmaceuticas que comprenden un inhibidor de pi3k para el tratamiento de cancer.
HK1199832A1 (en) Combination therapy using ribavirin as eif4e inhibitor
MX2016009226A (es) Combinaciones farmaceuticas.